Escherichia coli Nissle 1917 targets and restrains mouse b16 melanoma and 4T1 breast tumors through expression of azurin protein

Applied and Environmental Microbiology

Volumn 78, Issue 21, 2012, Pages 7603-7610

  Zhang, Yunlei ^a   Zhang, Youming ^a   Xia, Liqiu ^a   Zhang, Xiangli ^a   Ding, Xuezhi ^a   Yan, Fu ^a   Wu, Feng ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTITUMOR DRUGS; B16 MELANOMA; BACTERIAL INFECTIONS; BREAST TUMOR; CANCER THERAPY; E. COLI; IN-VITRO; INFLAMMATORY RESPONSE; NISSLE 1917; ORTHOTOPIC; SOLID TUMORS; THERAPEUTIC EFFECTS;

BACTERIA; BIOCHEMISTRY; DERMATOLOGY; ESCHERICHIA COLI; MAMMALS; ONCOLOGY; PROTEINS;

TUMORS;

ANTINEOPLASTIC AGENT; AZURIN;

BACTERIAL DISEASE; BIOTECHNOLOGY; CANCER; DISEASE TREATMENT; DRUG; EXPERIMENTAL STUDY; FECAL COLIFORM; GENE EXPRESSION; IMMUNOCOMPETENCE; INHIBITION; PROTEIN; RECOMBINATION; RODENT; TUMOR; WOMENS HEALTH;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CLASSIFICATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC ENGINEERING; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MICROBIOLOGY; MOUSE; PLASMID; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZURIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PLASMIDS;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI NISSLE 1917; MUS;

EID: 84868629296     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01390-12     Document Type: Article

References (43)

1. Agrawal N, et al. 2004. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. U.S.A.. 101:15172-15177.
2. Arribas B, et al. 2009. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br. J. Pharmacol. 157:1024-1033.
3. Avogadri F, et al. 2005. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 65:3920-3927.
4. Bettegowda C, et al. 2003. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl. Acad. Sci. U.S.A.. 100:15083-15088.
5. Chaudhari A, et al. 2007. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 46:1799-1810.
6. Cheng CM, et al. 2008. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther. 15:393-401.
7. de Vrese M, Schrezenmeir J. 2008. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111:1-66.
8. Diaz LA, Jr, et al. 2005. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol. Sci. 88:562-575.
9. Forbes NS, Munn LL, Fukumura D, Jain RK. 2003. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous
10. Fredriksen L, Mathiesen G, Sioud M, Eijsink VG. 2010. Cell wall anchoring of the 37-kilodalton oncofetal antigen by Lactobacillus plantarum
11. Grozdanov L, et al. 2002. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum
12. Guglielmetti S, et al. 2010. Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl. Environ. Microbiol. 76:3948-3958.
13. Guzy C, et al. 2008. The probiotic Escherichia coli strain Nissle 1917 induces
14. Hemilä H, Pakkanen R, Heikinheimo R, Palva ET, Palva I. 1992. Expression of the Erwinia carotovora polygalacturonase-encoding gene in Bacillus subtilis: role of signal peptide fusions on production of a heterologous protein. Gene 116:27-33.
15. Henker J, et al. 2008. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr. Infect. Dis. J. 27:494-499.
16. Henker J, et al. 2007. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 166: 311-318.
17. Homburg S, Oswald E, Hacker J, Dobrindt U. 2007. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol. Lett. 275:255-262.
18. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. 2007. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc. Natl. Acad. Sci. U.S.A.. 104:12879-12883. 1
19. Loessner H, et al. 2007. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol. 9:1529-1537. 2
20. Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM. 2007. Bacterial proteins and CpG-rich extrachromosomal DNA in potentialcancer therapy. Plasmid 57:4-17.
21. Mengesha A, et al. 2006. Development of a flexible and potent hypoxiainducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol. Ther. 5:1120-1128.
22. Presley LL, Wei B, Braun J, Borneman J. 2010. Bacteria associated with immunoregulatory cells in mice. Appl. Environ. Microbiol. 76:936-941.
23. Punj V, et al. 2004. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 23:2367-2378.
24. Sasaki T, et al. 2006. Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary
25. Smith AB, III, et al. 2005. Discodermolide analogues as the chemical component of combination bacteriolytic therapy. Bioorg. Med. Chem. Lett. 15:3623-3626.
26. Stark FC, Sad S, Krishnan L. 2009. Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection. Cancer Res. 69: 4327-4334. 2
27. Stritzker J, et al. 2007. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int. J. Med. Microbiol. 297:151-162.
28. Sturm A, et al. 2005. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via Toll-like receptor 2 signaling. Infect. Immun. 73:1452-1465.
29. Taylor BN, et al. 2009. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 69:537-546.
30. Thamm DH, et al. 2005. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin. Cancer Res. 11:4827-4834.
31. Toso JF, et al. 2002. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20:142-152.
32. Wei MQ, Mengesha A, Good D, Anné J. 2008. Bacterial targeted tumor therapy-dawn of a new era. Cancer Lett. 259:16-27.
33. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. 2008. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol. 10:1235-1248.
34. Wiemann B, Starnes CO. 1994. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:529-564.
35. Xiang S, Fruehauf J, Li CJ. 2006. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat. Biotechnol. 24:697-702.
36. Xu C, et al. 2007. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J. Gastroenterol. 13:939-944.
37. Yamada T, Hiraoka Y, Das Gupta TK, Chakrabarty AM. 2004. Regulation of mammalian cell growth and death by bacterial redox proteins: relevance to ecology and cancer therapy. Cell Cycle 3:752-755.
38. Yamada T, et al. 2004. Apoptosis or growth arrest: modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc. Natl. Acad. Sci. U.S.A.. 101:4770-4775.
39. Yamada T, et al. 2005. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell Microbiol. 7:1418-1431.
40. Yamada T, et al. 2009. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 8:2947-2958.
41. Yazawa K, et al. 2001. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res. Treatment 66:165-170.
42. Zhang L, et al. 2007. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res. 67:5859-5864.
43. Zhao M, et al. 2006. Targeted therapy with a Salmonella Typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 66:7647-7652.